VarmX announces publication of non-clinical data for VMX-C001
Repeat dosing up to 10 mg/kg for two weeks was well tolerated in rats and cynomolgus monkeys, and VMX-C001 restored thrombin generation suppressed by rivaroxaban.
See the latest news and media coverage for VarmX. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing anticoagulant reversal therapies
varmx.comLast updated
In short: VarmX advanced VMX-C001 into Phase 3 and secured CSL backing through a $117 million option deal.
Repeat dosing up to 10 mg/kg for two weeks was well tolerated in rats and cynomolgus monkeys, and VMX-C001 restored thrombin generation suppressed by rivaroxaban.
The name remains under review by the WHO, with publication as the recommended INN anticipated in September 2027, and VarmX will use 'relto' in everyday communications.
It is shortlisted for the Prix Galien USA Best Startup award and, with CSL, for Deal of the Year at the European Lifestars Awards.
CSL fully funds the global Phase 3 trial and gains an exclusive option to acquire VarmX, with up to $2.1bn in milestones.
Leiden, The Netherlands, 20 August 2026, VarmX, a biotech company developing innovative approaches to bypass direct oral anticoagulants targeting activated factor Xa (FXa inhibitors), enrolled...
Australia's CSL Limited has entered into an agreement with privately held Dutch biotech company, VarmX BV, to develop a new treatment to restore blood coagulation...
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse...
You have previously declined browser notifications for fd.nl. Go to browser settings and allow browser notifications for fd.nl. The exact steps depend on...
Track VarmX and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.